Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines

BMC Medical Genomics

Volumn 5, Issue , 2012, Pages

  Schlicker, Andreas ^a   Beran, Garry ^c   Chresta, Christine M ^c   McWalter, Gael ^c   Pritchard, Alison ^c   Weston, Susie ^c   Runswick, Sarah ^c   Davenport, Sara ^c   Heathcote, Kerry ^c   Castro, Denis Alferez ^c   Orphanides, George ^c   French, Tim ^c   Wessels, Lodewyk F A ^a,b,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c ASTRAZENECA   (United Kingdom)

^d Department of Molecular Carcinogenesis ^*  (Netherlands)

Author keywords

Cell lines; Colorectal cancer; Targeted therapy; Tumor subtyping

Indexed keywords

AURORA KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE; SRC PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL POPULATION; CELL SURVIVAL; COLORECTAL TUMOR; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MALE; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TISSUE CHARACTERIZATION; TUMOR CLASSIFICATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; DATABASES, GENETIC; EPITHELIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MESODERM; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; TRANSCRIPTOME;

EID: 84871676568     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-5-66     Document Type: Article

References (60)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Harvard report on cancer prevention. Volume 3: prevention of colon cancer in the united states. Tomeo CA, Colditz GA, Willett WC, Giovannucci E, Platz E, Rockhill B, Dart H, Hunter DJ, Cancer Causes Control 1999 10 167 180 10454062 (Pubitemid 29290451)
3. Molecular genetics of colorectal cancer. Fearon ER, Annu Rev Pathol 2011 6 479 507 10.1146/annurev-pathol-011110-130235 21090969
4. Biology of colorectal cancer. Saif MW, Chu E, Cancer J 2010 16 196 201 10.1097/PPO.0b013e3181e076af 20526096
5. Colon cancer: it's CIN or CIMP. Issa J-P, Clin Cancer Res 2008 14 5939 5940 10.1158/1078-0432.CCR-08-1596 18829469
6. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Sanchez JA, Krumroy L, Plummer S, Aung P, Merkulova A, Skacel M, DeJulius KL, Manilich E, Church JM, Casey G, Kalady MF, Br J Surg 2009 96 1196 1204 10.1002/bjs.6683 19787768
7. Molecular origins of cancer: molecular basis of colorectal cancer. Markowitz SD, Bertagnolli MM, N Engl J Med 2009 361 2449 2460 10.1056/NEJMra0804588 20018966
8. Microsatellite instability in colorectal cancer. Iacopetta B, Grieu F, Amanuel B, Asia Pac J Clin Oncol 2010 6 260 269 10.1111/j.1743-7563.2010.01335.x 21114775
9. Colorectal cancer epigenetics: complex simplicity. van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG, J Clin Oncol 2011 29 1382 1391 10.1200/JCO.2010.28.2319 21220596
10. Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions. Chibaudel B, Tournigand C, André T, Larsen AK, de Gramont A, Clin Colorectal Cancer 2010 9 269 273 10.3816/CCC.2010.n.039 21208840
11. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Cutsem EV, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F, J Clin Oncol 2011 29 2011 2019 10.1200/JCO.2010.33.5091 21502544
12. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Molinari F, Felicioni L, Buscarino M, Dosso SD, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Nicolantonio FD, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M, Clin Cancer Res 2011 17 4901 4914 10.1158/1078-0432.CCR-10-3137 21632860
13. Impact of KRAS mutations on management of colorectal carcinoma. Sullivan KM, Kozuch PS, Patholog Res Int 2011 2011 219309 21437184
14. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R, Nature 2012 483 100 103 10.1038/nature10868 22281684
15. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor BS, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD, Cancer Res 2010 70 2264 2273 10.1158/0008-5472.CAN-09-1577 20215513
16. Systematic identification of genomic markers of drug sensitivity in cancer cells. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH, Nature 2012 483 570 575 10.1038/nature11005 22460902
17. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, De Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA, Nature 2012 483 603 607 10.1038/nature11003 22460905
18. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R, Nicorici D, Hautaniemi S, Alazzouzi H, Mecklin J-P, Järvinen H, Hemminki A, Astola J, Schwartz S Jr, Aaltonen LA, Gastroenterology 2005 129 874 884 10.1053/j.gastro.2005.06.066 16143127 (Pubitemid 41242680)
19. Stage II colon cancer prognosis prediction by tumor gene expression profiling. Barrier A, Boelle P-Y, Roser F, Gregg J, Tse C, Brault D, Lacaine F, Houry S, Huguier M, Franc B, Flahault A, Lemoine A, Dudoit S, J Clin Oncol 2006 24 4685 4691 10.1200/JCO.2005.05.0229 16966692 (Pubitemid 46630932)
20. Molecular staging for survival prediction of colorectal cancer patients. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhøffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ, J Clin Oncol 2005 23 3526 3535 10.1200/JCO.2005.00.695 15908663
21. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A, Proc Natl Acad Sci USA 2008 105 19432 19437 10.1073/pnas.0806674105 19050079
22. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Lin Y-H, Friederichs J, Black MA, Mages J, Rosenberg R, Guilford PJ, Phillips V, Thompson-Fawcett M, Kasabov N, Toro T, Merrie AE, van Rij A, Yoon H-S, McCall JL, Siewert JR, Holzmann B, Reeve AE, Clin Cancer Res 2007 13 498 507 10.1158/1078-0432.CCR-05-2734 17255271 (Pubitemid 46225355)
23. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N, J Clin Oncol 2010 28 3937 3944 10.1200/JCO.2010.28.9538 20679606
24. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Velthuysen LV, Glas AM, Veer LJV, Tollenaar R, J Clin Oncol 2011 29 17 24 10.1200/JCO.2010.30.1077 21098318
25. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D, J Clin Oncol 2004 22 1564 1571 10.1200/JCO.2004.08.186 15051756 (Pubitemid 41079793)
26. Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D, Aaltonen LA, Arango D, Kruhøffer M, Orntoft TF, Andersen CL, Gruidl M, Kamath VP, Eschrich S, Yeatman TJ, Sieber OM, Clin Cancer Res 2009 15 7642 7651 10.1158/1078-0432.CCR- 09-1431 19996206
27. Gene expression in colorectal cancer. Birkenkamp-Demtroder K, Christensen LL, Olesen SH, Frederiksen CM, Laiho P, Aaltonen LA, Laurberg S, Sørensen FB, Hagemann R, ØRntoft TF, Cancer Res 2002 62 4352 4363 12154040 (Pubitemid 34827293)
28. Classification of Dukes' B and C colorectal cancers using expression arrays. Frederiksen CM, Knudsen S, Laurberg S, Ørntoft TF, J Cancer Res Clin Oncol 2003 129 263 271 12750996 (Pubitemid 36791681)
29. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C, Charafe-Jauffret E, Loriod B, Bachelart L, Montfort J, Victorero G, Viret F, Ollendorff V, Fert V, Giovaninni M, Delpero J-R, Nguyen C, Viens P, Monges G, Birnbaum D, Houlgatte R, Oncogene 2004 23 1377 1391 10.1038/sj.onc.1207262 14973550 (Pubitemid 38406833)
30. Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Kleivi K, Lind GE, Diep CB, Meling GI, Brandal LT, Nesland JM, Myklebost O, Rognum TO, Giercksky K-E, Skotheim RI, Lothe RA, Mol Cancer 2007 6 2 10.1186/1476-4598-6-2 17201907 (Pubitemid 46189688)
31. Synchronous global assessment of gene and protein expression in colorectal cancer progression. Kwong KY, Bloom GC, Yang I, Boulware D, Coppola D, Haseman J, Chen E, McGrath A, Makusky AJ, Taylor J, Steiner S, Zhou J, Yeatman TJ, Quackenbush J, Genomics 2005 86 142 158 10.1016/j.ygeno.2005.03.012 15951154 (Pubitemid 40917221)
32. EMT is the dominant program in human colon cancer. Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, Veer LV, Tollenaar RAEM, Jackson DB, Agrawal D, Dai H, Yeatman TJ, BMC Med Genomics 2011 4 9 21251323
33. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Oh SC, Park Y-Y, Park ES, Lim JY, Kim SM, Kim S-B, Kim J, Kim SC, Chu I-S, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee J-S, Gut 2012 61 1291 1298 10.1136/gutjnl-2011-300812 21997556
34. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez-Campos G, Calles A, Lopez-Asenjo J-A, Sanz-Ortega J, Fernandez-Perez C, Sastre J, Alfonso R, Caldes T, Martin-Sanchez F, Diaz-Rubio E, BMC Cancer 2012 12 260 10.1186/1471-2407-12- 260 22712570
35. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L, Ashkenazi A, Nat Med 2007 13 1070 1077 10.1038/nm1627 17767167 (Pubitemid 47517508)
36. Molecular target class is predictive of in vitro response profile. Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, Eastman S, McNeil E, Moy C, Wegrzyn R, Auger K, Hardwicke MA, Wooster R, Cancer Res 2010 70 3677 3686 10.1158/0008-5472.CAN-09-3788 20406975
37. Bioconductor: open software development for computational biology and bioinformatics. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JYH, Zhang J, Genome Biol 2004 5 80 10.1186/gb-2004-5-10-r80 15461798
38. affy-analysis of Affymetrix GeneChip data at the probe level. Gautier L, Cope L, Bolstad BM, Irizarry RA, Bioinformatics 2004 20 307 315 10.1093/bioinformatics/btg405 14960456 (Pubitemid 38262761)
39. KEGG for integration and interpretation of large-scale molecular data sets. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M, Nucleic Acids Res 2012 40 109 D114 10.1093/nar/gkr988 22080510
40. PANP-a New Method of Gene Detection on Oligonucleotide Expression Arrays. Warren P, Taylor D, Martini PGV, Jackson J, Bienkowska J, Proc. 7th IEEE Int. Conf. Bioinformatics and Bioengineering BIBE 2007 2007 108 115
41. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD, Gastroenterology 2010 138 958 968 10.1053/j.gastro.2009.11.005 19914252
42. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. de Sousa E, Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, van den Bergh SP, Rodermond H, Dekker E, van der Loos CM, Pals ST, van de Vijver MJ, Versteeg R, Richel DJ, Vermeulen L, Medema JP, Cell Stem Cell 2011 9 476 485 10.1016/j.stem.2011.10.008 22056143
43. A flexible R package for nonnegative matrix factorization. Gaujoux R, Seoighe C, BMC Bioinforma 2010 11 367 10.1186/1471-2105-11-367
44. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA, Proc Natl Acad Sci USA 2010 107 15449 15454 10.1073/pnas.1004900107 20713713
45. Discovering causal signaling pathways through gene-expression patterns. Parikh JR, Klinger B, Xia Y, Marto JA, Blüthgen N, Nucleic Acids Res 2010 38 Suppl 109 W117 20494976
46. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Proc Natl Acad Sci USA 2005 102 15545 15550 10.1073/pnas.0506580102 16199517 (Pubitemid 41528093)
47. PID: the pathway interaction database. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH, Nucleic Acids Res 2009 37 674 D679 10.1093/nar/gkn653 18832364
48. Novel search method for the discovery of functional relationships. Ramírez F, Lawyer G, Albrecht M, Bioinformatics 2012 28 269 276 10.1093/bioinformatics/btr631 22180409
49. Gene ontology: tool for the unification of biology. The gene ontology consortium. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G, Nat Genet 2000 25 25 29 10.1038/75556 10802651 (Pubitemid 30257031)
50. Comprehensive molecular characterization of human colon and rectal cancer. The Cancer Genome Atlas Network, Nature 2012 487 330 337 10.1038/nature11252 22810696
51. Recurrent R-spondin fusions in colon cancer. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, Guillory J, Ha C, Dijkgraaf GJP, Stinson J, Gnad F, Huntley MA, Degenhardt JD, Haverty PM, Bourgon R, Wang W, Koeppen H, Gentleman R, Starr TK, Zhang Z, Largaespada DA, Wu TD, de Sauvage FJ, Nature 2012 488 660 664 10.1038/nature11282 22895193
52. Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. March HN, Rust AG, Wright NA, ten Hoeve J, de Ridder J, Eldridge M, van der Weyden L, Berns A, Gadiot J, Uren A, Kemp R, Arends MJ, Wessels LFA, Winton DJ, Adams DJ, Nat Genet 2011 43 1202 1209 10.1038/ng.990 22057237
53. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Starr TK, Allaei R, Silverstein KAT, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O'Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW, Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT, Largaespada DA, Science 2009 323 1747 1750 10.1126/science.1163040 19251594
54. Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. Santilli G, Aronow BJ, Sala A, J Biol Chem 2003 278 38214 38219 10.1074/jbc.C300252200 12882985 (Pubitemid 37221710)
55. Clusterin inhibits apoptosis by interacting with activated Bax. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang C-Y, Nat Cell Biol 2005 7 909 915 10.1038/ncb1291 16113678 (Pubitemid 41486292)
56. DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. Wu K, Yang Y, Wang C, Davoli MA, D'Amico M, Li A, Cveklova K, Kozmik Z, Lisanti MP, Russell RG, Cvekl A, Pestell RG, J Biol Chem 2003 278 51673 51684 10.1074/jbc.M310021200 14525983 (Pubitemid 38020413)
57. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Smyrk TC, Watson P, Kaul K, Lynch HT, Cancer 2001 91 2417 2422 10.1002/1097-0142(20010615)91:12<2417::AID- CNCR1276>3.0.CO;2-U 11413533 (Pubitemid 32552830)
58. Gender differences in colorectal cancer incidence, mortality, hospitalizations and surgical procedures in Canada. Gao R-N, Neutel CI, Wai E, J Public Health 2008 30 194 201 10.1093/pubmed/fdn019
59. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Bufill JA, Ann Intern Med 1990 113 779 788 2240880 (Pubitemid 20369667)
60. Colorectal cancer cell lines lack the molecular heterogeneity of clinical colorectal tumors. Auman JT, McLeod HL, Clin Colorectal Cancer 2010 9 40 47 10.3816/CCC.2010.n.005 20100687